JS1-1-01 high-dose group
Sponsors
Tasly Pharmaceutical Group Co., Ltd
Conditions
Depression
Phase 2
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
CompletedNCT06259526
Start: 2023-12-26End: 2024-10-23Updated: 2025-11-19
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Not yet recruitingNCT07485595
Start: 2026-04-30End: 2026-12-31Target: 180Updated: 2026-04-08